68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?
Authors:
- Michael SommerauerMSMichael Sommerauer
- Jan-Karl BurkhardtJBJan-Karl Burkhardt
- Karl FrontzekKFKarl Frontzek
- Elisabeth RushingERElisabeth Rushing
- Alfred BuckABAlfred Buck
- Niklaus KrayenbuehlNKNiklaus Krayenbuehl
- Michael WellerMWMichael Weller
- Niklaus SchaeferNSNiklaus Schaefer
- Felix P. KuhnFKFelix P. Kuhn
Open Access
- 9 February 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (7) , 1021-1027
Abstract
DOTATATE-based radionuclides have added new options in the diagnosis and treatment of meningiomas; however, a reliable predictor of tumor growth has still not been established. We analyzed 64 meningiomas imaged with 68Ga-DOTATATE PET. Tumor growth rates were calculated by volumetric analysis of sequential MRI scans. Maximums of standardized uptake values (SUVmax) were correlated with tumor growth and covariates. World Health Organization (WHO) grades I and II meningiomas showed a correlation of SUVmax and tumor growth rate (meningiomas limited to the intracranial compartment: r = 0.757, P < .001, and transosseous growing meningiomas: r = 0.819, P = .024). SUVmax was significantly higher and the slope of the linear regression significantly steeper in transosseous compared with intracranial meningiomas (both P < .001). The association remained significant in multivariate analysis, and the prediction of tumor growth rate was independent of WHO grade. Anaplastic meningiomas showed no significant correlation of SUVmax and tumor growth. 68Ga-DOTATATE PET is a reliable predictor of tumor growth in WHO grades I and II meningiomas and provides additional information to conventional cross-sectional imaging modalities. Hence, 68Ga-DOTATATE PET can assist in selecting the time point for treatment initiation. Furthermore, meningiomas with fast tumor growth and transosseous expansion elicit the highest DOTATATE binding; therefore, they might be especially suited for DOTATATE-based therapy.Keywords
This publication has 33 references indexed in Scilit:
- Positron Emission Tomography Imaging of Meningioma in Clinical PracticeNeurosurgery, 2012
- Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT Treatment Planning for Meningioma: First ExperienceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytomaNeuro-Oncology, 2011
- Multiple meningioma with different grades of malignancy: Case report with genetic analysis applying single-nucleotide polymorphism array and classical cytogeneticsPathology - Research and Practice, 2011
- Modern meningioma imaging techniquesJournal of Neuro-Oncology, 2010
- Intracranial meningiomas of atypical (WHO grade II) histologyJournal of Neuro-Oncology, 2010
- [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planningRadiation Oncology, 2009
- Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathwaysActa Oncologica, 2009
- Review of meningioma histopathologyNeurosurgical Focus, 2007
- Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growthThe Journal of Clinical Endocrinology & Metabolism, 1992